×
ZJYL shares climbed roughly 74% over the trailing 30 days, rising from about $1.91 in mid-October to about $3.33 in the latest session. The advance was led by the closing of the $159.4 million Huaxia Qiying acquisition and related corporate updates, amplified by momentum trading in a thinly traded small cap.
Anbio Biotechnology (NNNN) climbed from a $3.60 close on Nov 18 to $3.75, a +4.17% gain, with the move taking place during regular Nasdaq trading hours. No verified news or fundamental catalyst found: no company release, SEC filing, analyst action, or sector event published before the move explains it. The gain is likely technical — a low-liquidity micro-cap bounce after a -87% 52-week decline, consistent with a stock that averaged a ±4.0% daily swing across the last 60 sessions.
RGNT dropped from a $1.14 close on Nov. 18 to $1.00, a -12.28% move (-$0.14), during regular-session trading on the NYSE American. No verified news or fundamental catalyst found: no filing, release, or analyst action coincided with the decline, which is consistent with thin-liquidity liquidation in a pre-revenue micro-cap that averages a ~3.5% daily swing.
NXGL fell -5.03%, sliding from the prior close of $3.58 to $3.395, with the decline occurring during Thursday's regular session. The catalyst was the company's pre-open announcement that it postponed its third-quarter results and corporate update call, originally scheduled for today, to November 24 — delaying clarity on the pending Fountainhead LifeSciences merger and recapitalization.
The central target is $8 per share , which implies a move of roughly 61% above the latest price near $4.97 . This $8 figure is not an analyst consensus . Precision Optics has only one published price target, so the objective rests on that single target and the stock's prior all-time-high zone near $7.85.
Intuitive Surgical ( ISRG ) delivered 22% revenue growth in its latest quarter, but shares fell sharply on a $450 million antitrust settlement, slower U.S. procedure growth, and planned instrument price cuts. United Parcel Service ( UPS ) beat estimates and raised full-year guidance, with shares climbing roughly 9% following its report as margin-focused strategy gains traction.
Regentis Biomaterials (RGNT) shares fell approximately 16.6% over the last 30 days, declining from about $1.51 to near $1.26 as of mid-November. The pullback extended a longer downtrend, with the stock down roughly 34% over the last quarter.
Bionano Genomics (BNGO) shares fell roughly 26% over the last 30 days, sliding from about $1.37 to near $1.02, as a sharp mid-September rally fully unwound. A third-quarter earnings miss in early November, with revenue and per-share loss both coming in below consensus, accelerated the decline in the final stretch of the period.
KRMD slipped to $3.62 in early regular-session trading Friday, a -2.03% decline from Thursday's $3.69 close. No verified news or fundamental catalyst found for the pullback; the move is likely continued profit-taking after shares jumped +23.10% on Nov. 11 and then dropped -5.14% on Nov. 12, with the stock's typical daily swing near 2%.
ISRG is a pure-play leader in robotic-assisted surgery, while SYK is a diversified medical technology company spanning orthopaedics, MedSurg, and neurotechnology. In recent market activity, SYK has shown greater relative resilience, while ISRG has carried a materially steeper year-to-date drawdown.
The central target of $1.00 is a fallback milestone tied to the Nasdaq $1.00 minimum bid price rule, not an analyst consensus — it is not a published "stock price target" from Wall Street. At a latest verified price near $0.81 , reaching $1.00 requires a gain of roughly 23% .
Third quarter 2026 net revenue reached $1.01 million, up 51% year over year and marking a 13th consecutive quarter of growth. Net loss narrowed to $0.27 per share, an improvement from a $0.38 per share loss in the prior-year quarter and better than consensus estimates.
The central target discussed here is $1.25 , the arithmetic mean of two verified analyst price targets currently in circulation — a low of $1.00 and a high of $1.50. With shares recently trading near $0.29 , reaching $1.25 would require a gain of roughly 330% , a very large move for any listed company.
Milestone Scientific Inc. (NYSE: MLSS) is scheduled to report results for its third quarter ended September 30, 2026, before the market opens on Friday, November 13, 2026, followed by a conference call at 8:30 AM Eastern Time. Management has guided third-quarter revenue to roughly $2.3 million to $2.5 million, a sequential step down from $2.8 million in the second quarter, reflecting the absence of two large non-recurring international dental orders and typical seasonal softness.
The central price target of $22.50 is the arithmetic mean of two verified analyst price targets ($22 and $23) from Maxim Group and Lake Street, both carrying Buy ratings. With DXR trading near $8.46, reaching $22.50 would require a gain of roughly 166% , a very large move for a micro-cap medical technology company.
Daxor Corporation (DXR) is expected to report its fiscal third-quarter 2026 results around November 13, 2026 , covering the period ended September 30, 2026. The company develops the BVA-100 blood-volume analyzer, and management reported kit sales up 16% year-over-year in the first half of 2026.
The $8 price target comes from a single analyst's public coverage initiation, not a multi-analyst consensus, so it should be read as one firm's view rather than a market-wide forecast. Precision Optics Corporation, Inc. (POCI) last traded near $5.00, meaning the stock would need to rise roughly 60% to reach $8.
Pending acquisition is the defining catalyst. MIMEDX has agreed to acquire Sanara MedTech for $33.00 in cash plus 0.4735 shares of MIMEDX per share, a deal valued at roughly $350 million that remains subject to antitrust review (the Federal Trade Commission issued a "Second Request" in October 2026). Strategic positioning is focused and differentiated. Sanara has streamlined into a pure-play surgical wound-care company with three core technologies and a hospital-direct model that is insulated from direct reimbursement risk.
Sanara MedTech Inc. is a medical technology company that develops, markets, and distributes surgical solutions for soft tissue repair and bone fusion, primarily used in operating rooms and surgical centers across the United States. The company trades on the Nasdaq under the ticker SMTI and is headquartered in Fort Worth, Texas.
Stereotaxis (STXS) declined roughly 17.9% over the last 30 days, falling from a closing price of $1.06 on October 13, 2026 to approximately $0.87 as of mid-November 2026. The stock's slide reflects a third-quarter earnings miss, weaker-than-expected recurring revenue, and a convertible note financing that underscored the company's need for additional capital.